Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05053035 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
A Phase 2 study, sponsored by Alector.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05053035 is a Phase 2 study that was terminated before completion, run by Alector. The registered enrollment target is 5 participants.
The verdict
NCT05053035, a Phase 2 study, was terminated before completion, sponsored by Alector.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
Interventions
- DRUG Placebo
- DRUG AL001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-09-02 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05053035
The ClinicalTrials.gov registry entry for NCT05053035 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05053035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05053035 about?
NCT05053035 is a clinical study titled "A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS". A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
What is the current status of trial NCT05053035?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-09-02. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05053035?
The interventions under investigation include: Placebo (DRUG), AL001 (DRUG).
Who is sponsoring clinical trial NCT05053035?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.